Insmed (INSM) to Release Quarterly Earnings on Thursday

Insmed (NASDAQ:INSM) is projected to announce its Q4 2025 results before the market opens on Thursday, February 19th. Analysts expect the company to announce earnings of ($1.25) per share and revenue of $263.9660 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 19, 2026 at 8:00 AM ET.

Insmed Stock Performance

Shares of NASDAQ INSM opened at $148.43 on Thursday. The stock’s 50-day moving average is $171.34 and its 200 day moving average is $161.28. The stock has a market cap of $31.66 billion, a price-to-earnings ratio of -23.98 and a beta of 1.11. Insmed has a 1-year low of $60.40 and a 1-year high of $212.75. The company has a current ratio of 4.63, a quick ratio of 4.34 and a debt-to-equity ratio of 0.59.

Analyst Ratings Changes

INSM has been the topic of several research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Insmed in a research note on Thursday, January 22nd. Truist Financial set a $205.00 target price on shares of Insmed in a report on Monday, January 12th. UBS Group lowered their price target on shares of Insmed from $223.00 to $215.00 and set a “buy” rating for the company in a research note on Tuesday, January 6th. Wells Fargo & Company set a $195.00 price target on shares of Insmed in a research report on Thursday, December 18th. Finally, Cantor Fitzgerald raised their price objective on Insmed from $216.00 to $230.00 and gave the company an “overweight” rating in a research note on Tuesday, December 16th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $204.24.

Insider Transactions at Insmed

In other news, CEO William Lewis sold 19,215 shares of the company’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $169.00, for a total value of $3,247,335.00. Following the sale, the chief executive officer directly owned 306,891 shares of the company’s stock, valued at $51,864,579. This represents a 5.89% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Elizabeth M. Anderson sold 10,000 shares of Insmed stock in a transaction dated Friday, November 14th. The shares were sold at an average price of $195.87, for a total transaction of $1,958,700.00. Following the transaction, the director directly owned 63,729 shares of the company’s stock, valued at approximately $12,482,599.23. This trade represents a 13.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 258,253 shares of company stock worth $46,281,042 in the last ninety days. 3.00% of the stock is owned by company insiders.

Hedge Funds Weigh In On Insmed

Several large investors have recently made changes to their positions in INSM. CIBC Private Wealth Group LLC boosted its position in shares of Insmed by 42.1% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 53 shares in the last quarter. Johnson Financial Group Inc. purchased a new position in Insmed during the third quarter valued at $67,000. EverSource Wealth Advisors LLC boosted its holdings in Insmed by 65.6% in the second quarter. EverSource Wealth Advisors LLC now owns 664 shares of the biopharmaceutical company’s stock worth $67,000 after acquiring an additional 263 shares in the last quarter. Northwestern Mutual Wealth Management Co. boosted its holdings in Insmed by 277.2% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 430 shares of the biopharmaceutical company’s stock worth $75,000 after acquiring an additional 316 shares in the last quarter. Finally, Zions Bancorporation National Association UT purchased a new stake in shares of Insmed in the fourth quarter worth $112,000.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.